We are committed to finding effective treatment for life-threatening infectious diseases.
A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology
Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria
New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent
iNtODEWORLD’s Chief Operating Officer, H. Tim Min, and Project Coordinator, Minerva Marcano, will be attending the 2nd inaugural Phage Futures Congress 2020 being held in Washington D.C. from February 5-6, 2020. The conference is first of its kind to discuss how to translate phage-based application......
iNtRON Biotechnology attended the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14, 2020. J.P. Morgan’s Healthcare Conference is Wall Street’s premier investor conference aimed exclusively towards companies defining the healthcare industry. J.P. Morgan Healthcare Conference continues their tradition of......
Investment in the treatment of rare and orphan diseases continues to significantly grow as the pharmaceutical and biotech industry diverges their attention to novel drug development. Despite the momentous shift in attention to smaller patient populations affected by rare disease, Contract Research Organizations (CROs) now face......
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
